Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 552-557, February 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daly, P. F.
Right arrow Articles by Cohen, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, P. F.
Right arrow Articles by Cohen, J. S.

Regulation of the Cytidine Phospholipid Pathways in Human Cancer Cells and Effects of 1-ß-D-Arabinofuranosylcytosine: A Noninvasive 31P Nuclear Magnetic Resonance Study

Peter F. Daly1, Gerhard Zugmaier, David Sandler, Mary Carpen, C. E. Myers and J. S. Cohen2

Pediatric Oncology Branch [P. F. D., M. C.] and Medicine Branch [G. Z., D. S., C. E. M., J. S. C.], National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Using 31P nuclear magnetic resonance spectroscopy we have noninvasively observed metabolic control through the cytidine pathways of phosphatidylcholine and phosphatidylethanolamine synthesis in intact actively metabolizing MDA-MB-231 human breast cancer cells. Perfusion with the phospholipid precursors ethanolamine or choline (2 mM) indicates that the cytidylyltransferase enzymes are rate limiting for both pathways. Complete inhibition of choline kinase with ethanolamine allowed the observation of the utilization of phosphocholine by the rate-limiting enzyme choline-phosphate cytidylyltransferase. The rate was dependent on the phosphocholine concentration. Inhibition of glycerophosphorylcholine phosphodiesterase with accumulation of substrate was also observed and allows an estimate of the flux through the degradative pathways.

The human lymphoma cell line MOLT-4 was also found to contain high levels of phosphocholine and phosphoethanolamine. The levels of these precursors in the MOLT-4 line are lowered by 40% after 6 h when perfused with high dose 1-ß-D-arabinofuranosylcytosine (Ara-C) (400 µm) but are unaffected by 2 µm Ara-C or dideoxycytidine. High dose Ara-C also resulted in lysis in 8–10 h. However, the MDA-MB-231 cell line which is not sensitive to Ara-C showed no change in its spectrum when perfused with Ara-C. A potential mechanism based on classic phospholipid metabolism for the lytic effect of high dose Ara-C is discussed.

1 Present address: Pittsburgh NMR Institute, 3260 Fifth Avenue, Pittsburgh, PA 15213.

2 To whom requests for reprints should be addressed, at Clinical Pharmacology Branch, National Cancer Institute, Building 10, Room 6N119, Bethesda, MD 20892.

Received 12/15/88. Revised 5/22/89. Accepted 10/25/89.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Sterin, J. S. Cohen, Y. Mardor, E. Berman, and I. Ringel
Levels of Phospholipid Metabolites in Breast Cancer Cells Treated with Antimitotic Drugs: A 31P-Magnetic Resonance Spectroscopy Study
Cancer Res., October 1, 2001; 61(20): 7536 - 7543.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.